Oct 29, 2026 9:00am EDT Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
Oct 26, 2026 7:55am EDT Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Oct 07, 2026 8:48am EDT Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Sep 23, 2026 7:33am EDT Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Sep 16, 2026 7:30am EDT Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Sep 08, 2026 9:00am EDT Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Aug 20, 2026 8:52am EDT Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Aug 17, 2026 8:52am EDT Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Aug 13, 2026 8:00am EDT Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
